Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy.

Wark L, Quon H, Ong A, Drachenberg D, Rangel-Pozzo A, Mai S.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1165. doi: 10.3390/cancers11081165.

2.

Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large Canadian multi-institutional database.

Oake JD, Patel P, Lavallée LT, Lattouf JB, Saarela O, Klotz L, Moore RB, Kapoor A, Finelli A, Rendon RA, Kawakami J, So A, Drachenberg DE.

Can Urol Assoc J. 2019 Jul 23. doi: 10.5489/cuaj.5941. [Epub ahead of print]

PMID:
31348746
3.

Advancing Risk Assessment of Intermediate Risk Prostate Cancer Patients.

Drachenberg D, Awe JA, Rangel Pozzo A, Saranchuk J, Mai S.

Cancers (Basel). 2019 Jun 20;11(6). pii: E855. doi: 10.3390/cancers11060855.

4.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.

PMID:
31157964
5.

Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy.

McAlpine K, Lavallée LT, Stacey D, Moodley P, Cagiannos I, Morash C, Black PC, Kulkarni GS, Shayegan B, Kassouf W, Siemens R, So A, Leveridge MJ, Boorjian SA, Daneshmand S, Smith AB, Power N, Izawa J, Drachenberg DE, Fairey A, Rendon RA, Breau RH.

J Urol. 2019 May 17:101097JU0000000000000341. doi: 10.1097/JU.0000000000000341. [Epub ahead of print]

PMID:
31099720
6.

Thoracoabdominal Approach for Large Retroperitoneal Masses: Case Series and Review.

Venkat S, Matteliano A, Drachenberg D.

Case Rep Urol. 2019 Mar 10;2019:8071025. doi: 10.1155/2019/8071025. eCollection 2019.

7.

Long-Term Surveillance of Complex Cystic Renal Masses and Heterogeneity of Bosniak 3 Lesions.

Pruthi DK, Liu Q, Kirkpatrick IDC, Gelfond J, Drachenberg DE.

J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000144. [Epub ahead of print] No abstract available.

PMID:
30747876
8.

Case - Combined endoscopic cautery and over-the-scope-clip closure of an acquired rectourethral fistula: A novel surgical repair technique.

Oake JD, Drachenberg DE, Hochman D.

Can Urol Assoc J. 2019 May;13(5):E151-E153. doi: 10.5489/cuaj.5624. Epub 2018 Oct 15. No abstract available.

9.

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F.

BMC Urol. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.

10.

Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Kassouf W, Monteiro LL, Drachenberg DE, Fairey AS, Finelli A, Kapoor A, Lattouf JB, Leveridge MJ, Power NE, Pouliot F, Rendon RA, Sabbagh R, So AI, Tanguay S, Breau RH.

Can Urol Assoc J. 2018 Aug;12(8):231-238. doi: 10.5489/cuaj.5462. Epub 2018 May 31. No abstract available.

11.

Long-Term Surveillance of Complex Cystic Renal Masses and Heterogeneity of Bosniak 3 Lesions.

Pruthi DK, Liu Q, Kirkpatrick IDC, Gelfond J, Drachenberg DE.

J Urol. 2018 Dec;200(6):1192-1199. doi: 10.1016/j.juro.2018.07.063. Epub 2018 Aug 1.

PMID:
30076907
12.

Images - Isolated caval recurrence of renal cell carcinoma.

Oake JD, Semenchuk JA, Drachenberg DE.

Can Urol Assoc J. 2018 Jul 24. doi: 10.5489/cuaj.5245. [Epub ahead of print] No abstract available.

13.

Describing perspectives of health care professionals on active surveillance for the management of prostate cancer.

Pang K, Fitch M, Ouellet V, Chevalier S, Drachenberg DE, Finelli A, Lattouf JB, So A, Sutcliffe S, Tanguay S, Saad F, Mes-Masson AM.

BMC Health Serv Res. 2018 Jun 8;18(1):430. doi: 10.1186/s12913-018-3273-9.

14.

Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M.

Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.

15.

Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma.

Locke JA, Hamidizadeh R, Kassouf W, Rendon RA, Bell D, Izawa J, Chin J, Kapoor A, Shayegen B, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey AS, Jacobson NE, Drachenberg DE, Cagiannos I, So AI, Black PC.

Can Urol Assoc J. 2018 Aug;12(8):243-251. doi: 10.5489/cuaj.5377. Epub 2018 Apr 12.

16.

Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Kassouf W, Aprikian A, Saad F, Breau RH, Kulkarni G, Guttman DM, Bagshaw K, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Brimo F, Chung P, Drachenberg D, Fradet Y, Jacobsen N, Morash C, Shayegan B, Gotto G, Zlotta A, Fleshner N, Siemens DR, Black PC.

Can Urol Assoc J. 2018 Jul;12(7):E281-E297. doi: 10.5489/cuaj.5246. Epub 2018 Mar 19. No abstract available.

17.

Canadian Men's perspectives about active surveillance in prostate cancer: need for guidance and resources.

Fitch M, Pang K, Ouellet V, Loiselle C, Alibhai S, Chevalier S, Drachenberg DE, Finelli A, Lattouf JB, Sutcliffe S, So A, Tanguay S, Saad F, Mes-Masson AM.

BMC Urol. 2017 Oct 27;17(1):98. doi: 10.1186/s12894-017-0290-7.

18.

Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective.

Lawson KA, Saarela O, Liu Z, Lavallée LT, Breau RH, Wood L, Jewett MAS, Kapoor A, Tanguay S, Moore RB, Rendon R, Pouliot F, Black PC, Kawakami J, Drachenberg D, Finelli A.

Can Urol Assoc J. 2017 Aug;11(8):232-237. doi: 10.5489/cuaj.4397.

19.

Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative.

Bansal RK, Tanguay S, Finelli A, Rendon R, Moore RB, Breau RH, Lacombe L, Black PC, Kawakami J, Drachenberg D, Pautler S, Saarela O, Liu Z, Jewett MAS, Kapoor A.

Can Urol Assoc J. 2017 Jun;11(6):182-187. doi: 10.5489/cuaj.4264.

20.

Plasma microRNA signature is associated with risk stratification in prostate cancer patients.

Al-Qatati A, Akrong C, Stevic I, Pantel K, Awe J, Saranchuk J, Drachenberg D, Mai S, Schwarzenbach H.

Int J Cancer. 2017 Sep 15;141(6):1231-1239. doi: 10.1002/ijc.30815. Epub 2017 Jun 23.

Supplemental Content

Loading ...
Support Center